Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13676 - 13700 of 14603 in total
beta-Hydroxyisovaleric acid is under investigation in clinical trial NCT03018496 (Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.).
Investigational
Matched Description: … NCT03018496 (Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and
Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M).
Investigational
Matched Description: … Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in …
Ladarixin is under investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual Β-Cell Function).
Investigational
Matched Description: … investigation in clinical trial NCT04628481 (A Study of Oral Ladarixin in New-onset Type 1 Diabetes and
Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).
Investigational
Matched Description: … Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary …
Plumbagin is a compound investigated for its anticancer activity. It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.
Investigational
Matched Description: … It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.[A253102] …
DA-8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation).
Investigational
Matched Description: … -8031 is under investigation in clinical trial NCT01798667 (Clinical Trial to Evaluate the Efficacy and
NYX-2925 is under investigation in clinical trial NCT04146896 (Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)).
Investigational
Matched Description: … NYX-2925 is under investigation in clinical trial NCT04146896 (Efficacy and Safety of NYX-2925 in Subjects …
BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
Investigational
Matched Description: … BZL101 targets diseased cells while leaving normal cells healthy and intact. …
Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.
Experimental
Matched Description: … It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose. …
Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).
Investigational
Matched Description: … Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and
MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Investigational
Matched Description: … MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK …
ASC has been investigated for the screening of Patients Undergoing Screening or Surveillance Colonoscopy.
Investigational
Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Experimental
Matched Description: … Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic …
Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer).
Investigational
Matched Description: … Fluoromisonidazole F-18 is under investigation in clinical trial NCT01507428 (Study of Positron Emission Tomography and
KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and hip replacement and may protect against renal injury associated with contrast media. Several studies...
Investigational
Matched Description: … hip replacement and may protect against renal injury associated with contrast media. ... may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect repair, and
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to the family of drugs called metalloporphyrin complexes. Also called gadolinium texaphyrin.
Investigational
Matched Description: … cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and
Investigational
Displaying drugs 13676 - 13700 of 14603 in total